Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'-[γ-thio]triphosphate-[35S] binding

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 119-126

  Malmberg, Åsa ^a   Mikaels, Åsa ^a   Mohell, Nina ^a  

^a Astra Arcus AB ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; GUANINE NUCLEOTIDE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; MAGNESIUM; PERTUSSIS TOXIN; PRECLAMOL; QUINPIROLE; RACLOPRIDE; SODIUM;

AGONIST; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HALOPERIDOL; HUMANS; MICE; PERTUSSIS TOXIN; QUINPIROLE; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; TETRAHYDRONAPHTHALENES; VIRULENCE FACTORS, BORDETELLA;

EID: 0031969706     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Burstein ES, Spalding TA and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
2. 3 dopamine receptors to G-proteins. FEES Lett 315:223-226.
3. 2 dopamine receptors. Mol Pharmacol 45:51-60.
4. Costa T, Ogino Y, Munson PJ, Onaran HO and Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560.
5. Creese I (1983) Classical and atypical antipsychotic drugs: new insights. Trends Neurosci 6:479-481.
6. De Lean A, Stadel JM and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled b-adrenergic receptor. J Biol Chem 255:7108-7117.
7. 3 dopamine receptor. J Pharmacol Exp Ther 268:417-426.
8. 2(short) dopamine receptors. Biochem Soc Trans 23:91S.
9. Gether U, Ballesteros JA, Seifert R, Sandersbush E, Weinstein H and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor-agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
10. 3 receptor ligand, (+)-UH232, is a partial agonist. Eur J Pharmacol 282:R3-R4.
11. 3 receptor. J Neural Transm 103:1163-1175.
12. 2 dopamine receptors from the high-to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem 44:1925-1935.
13. 3H-Dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodium. Life Sci 30:1587-1595.
14. 2-adrenergic receptors by sodium. J Biol Chem 265:21590-21595.
15. Kenakin T (1995) Pharmacological Proteus? Trends Pharmacol Sci 16:256-258.
16. Kent RS, De Lean A and Lefkowitz RJ (1980) A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14-23.
17. 4 dopamine receptors determined in transfected cell lines. Clin Neuropharmacol 18:S25-S33.
18. Lazareno S, Farries T and Birdsall NJM (1993) Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4. Life Sci 52:449-456.
19. Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
21. Malmberg, Å., Backlund Höök B, Johansson AM and Hacksell U (1996) Novel (R)-2-amino-5-fluorotetralins - dopaminergic antagonists and inverse agonists. J Med Chem 39:4421-4429.
22. 3 receptors. Mol Pharmacol 43:749-754.
23. 3 receptors: Effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797.
24. Markwell MAK, Haas SM, Bieber LL and Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206-210.
25. Munson PJ and Rodhard D (1980) LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
26. 2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol 39: 733-739.
27. 2 receptors? J Neural Transm 92:213-220.
28. 3 dopamine receptors. J Neurosci 14:1463-1476.
29. Reynolds GP (1992) Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 13:116-121.
30. 2-adrenergic receptor. J Biol Chem 268:4625-4636.
31. 2 receptors. NeuroReport 6:329-332.
32. 3 receptor: Basic and clinical aspects. Clin Neuropharmacol 16:295-314.
33. 3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells. Br J Pharmacol 111:391-393.
34. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
35. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284.
36. 3) as a target for neuroleptics. Nature (Lond) 347:146-151.
37. 2 receptor. Eur J Pharmacol 225:331-337.
38. 1B receptor subtype. J Biol Chem 269:27925-27931.
39. 2 receptors for dopamine by a mechanism independent of receptor coupling to guanyl nucleotide binding proteins. Naunyn-Schmiedebergs Arch Pharmacol 339: 374-382.
40. 2 dopamine receptors by magnesium and sodium ions. J Neurochem 45:1842-1849.
41. Wieland T and Jakobs KH (1994) Measurements of receptor-stimulated guanosine 5′-O-(γ-thio)triphosphate binding by G proteins, in Heterotrimeric G Proteins (Iyengar R ed) pp 3-13, Academic Press, Inc. San Diego, CA.